Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone353-1634-7800
Debt
Debt-to-Equity Ratio0.54
Current Ratio3.76
Quick Ratio3.62
Price-To-Earnings
Trailing P/E Ratio18.18
Forward P/E Ratio14.93
P/E Growth0.96
Sales & Book Value
Annual Sales$1.62 billion
Price / Sales6.49
Cash Flow$12.8558 per share
Price / Cash13.52
Book Value$45.26 per share
Price / Book3.84
Profitability
EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Net Margins24.20%
Return on Equity25.47%
Return on Assets13.30%
Miscellaneous
Employees1,210
Outstanding Shares60,410,000
Market Cap$10.64 billion
Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions
What is Jazz Pharmaceuticals' stock symbol?
Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported $3.49 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.23 by $0.26. The specialty pharmaceutical company earned $500.48 million during the quarter, compared to analyst estimates of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. View Jazz Pharmaceuticals' Earnings History.
When is Jazz Pharmaceuticals' next earnings date?
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?
Jazz Pharmaceuticals updated its FY18 earnings guidance on Tuesday, August, 7th. The company provided earnings per share guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.04. The company issued revenue guidance of $1880-1930 million, compared to the consensus revenue estimate of $1.90 billion.
What price target have analysts set for JAZZ?
21 Wall Street analysts have issued 1 year price objectives for Jazz Pharmaceuticals' stock. Their predictions range from $150.00 to $219.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $190.80 in the next year. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.
What is the consensus analysts' recommendation for Jazz Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.
What are Wall Street analysts saying about Jazz Pharmaceuticals stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We highlighted after 1Q that management seemed to be taking a decidedly conservative approach to guidance this year, and this quarter we again see a healthy beat with little or no full-year raise. We still think guidance is a bit conservative (we’re near the high end on REV and EPS), but besides a small revenue drag from the sale of Prialt, unfortunately there was a key underperformer holding Jazz guidance back: Vyxeos. Jazz’s newest growth driver, from its most recent acquisition, only grew modestly QoQ, missed consensus for the second straight quarter, and Jazz lowered the product’s 2018 guidance 12% at the midpoint to $115-135M." (8/9/2018)
- 2. According to Zacks Investment Research, "After lower-than-expected sales in 2017, Jazz’ sleep disorder drug, Xyrem witnessed improved volume trends in Q1. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate JZP-110 complements its existing sleep disorder portfolio. Meanwhile, its newest drug Vyxeos is enjoying improving demand trends. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year. However, Jazz has been facing supply constraints for leukemia drug, Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018. Estimate movement has been mixed ahead of the company’s Q2 earnings release. Jazz has a mixed record of earnings surprises in recent quarters." (7/16/2018)
- 3. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)
- 4. Cantor Fitzgerald analysts commented, "JAZZ’s purchase of PRV makes strategic sense to us. This morning, the acquisition of a Priority Review Voucher (PRV) by JAZZ was disclosed. The company is paying $110 million in cash for a PRV owned by Spark Therapeutics (ONCE, Overweight rated covered by Elemer Piros). Particularly when applied to a speed-to-market situation, we believe the PRV could be useful for JAZZ." (4/30/2018)
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF) and Alnylam Pharmaceuticals (ALNY).
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the folowing people:
- Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
- Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
- Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
- Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)
- Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 55)
Has Jazz Pharmaceuticals been receiving favorable news coverage?
News coverage about JAZZ stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a media and rumor sentiment score of 0.03 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 45.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Jazz Pharmaceuticals.
Who are Jazz Pharmaceuticals' major shareholders?
Jazz Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (11.01%), Putnam Investments LLC (8.13%), BlackRock Inc. (7.25%), Bank of New York Mellon Corp (2.46%), Partner Fund Management L.P. (2.05%) and Boston Partners (1.81%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.
Which institutional investors are selling Jazz Pharmaceuticals stock?
JAZZ stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Cadian Capital Management LP, Senator Investment Group LP, Waddell & Reed Financial Inc., Bank of New York Mellon Corp, Renaissance Technologies LLC, Virginia Retirement Systems ET AL and Summit Trail Advisors LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy and Rick E Winningham. View Insider Buying and Selling for Jazz Pharmaceuticals.
Which institutional investors are buying Jazz Pharmaceuticals stock?
JAZZ stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Congress Asset Management Co. MA, AGF Investments Inc., Voya Investment Management LLC, Fiera Capital Corp, Acadian Asset Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Jazz Pharmaceuticals.
How do I buy shares of Jazz Pharmaceuticals?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals' stock price today?
One share of JAZZ stock can currently be purchased for approximately $173.81.
How big of a company is Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a market capitalization of $10.64 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.
How can I contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]
MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
